AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
Recruiting now
Conditions studied: Chronic Heart Failure, Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Congestive Heart Failure Chronic
In brief
The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure (CHF). The main questions it aims to answer are: * Can continuous remote monitoring reduce hospital admissions (emergency visits and hospitalizations) by 20% compared to standard care? * Does wearable-based remote monitoring improve functional, biochemical, and instrumental parameters in CHF patients? Researchers will compare patients using the wearable device (intervention group) to those receiving standard clinical follow-up (control group) to assess whether AI-driven monitoring leads to fewer hospitalizations, better disease management, and improved quality of life. Participants will: * Wear the EmbracePlus (Empatica Inc.) device continuously for six months (intervention group only). * Have their biometric data (SpO₂, HRV, EDA, respiratory rate, temperature, sleep quality) monitored remotely. * Receive automated alerts and teleconsultations if abnormal physiological changes are detected. * Attend scheduled follow-up visits (remote and in-person) for clinical evaluation and treatment adjustments. The study aims to provide real-world evidence on whether integrating wearable health technology with AI analytics can enhance CHF management and improve patient outcomes.
Key facts
- Study ID
- NCT06909682
- Run by
- University of Salerno
- People needed
- 205
- Starts
- 2025-08-01
- Expected to finish
- 2027-02-02
- Last updated by the study team
- 2026-03-11
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years (adults of any sex)
- Confirmed diagnosis of chronic heart failure (CHF) for at least 6 months prior to screening
- Stable on optimized heart failure therapy for at least one month before enrollment
- Any left ventricular ejection fraction (LVEF) classification, including:
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Mid-Range Ejection Fraction (HFmrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- NYHA Functional Class I, II, or III
- History of at least one hospital admission or outpatient visit in the past 12 months requiring intravenous (IV) diuretics, vasodilators, or inotropes for CHF exacerbation
- Ability to provide written informed consent or availability of a legally authorized representative Exclusion Criteria
- NYHA Functional Class IV or anticipated heart transplant or ventricular assist device (VAD) implantation within 6 months of screening
- Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or dialysis dependence
- Terminal comorbidities (e.g., advanced cancer, end-stage pulmonary disease) significantly limiting life expectancy
- Pregnancy
- Presence of skin conditions or allergies preventing prolonged use of a wearable device
- Inability to comply with study procedures (e.g., cognitive impairment, significant psychiatric disorders)
Where it is running
- Hospital University San Giovanni di Dio and Ruggi d'Aragona — Salerno, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.